Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

149 49,465

Net cash provided by operating

activities 282,777 274,321

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (55,689) (70,887)

Acquisition of intangible assets (25,575) (99,152)

Investment in third party (6,242) -

Proceeds from sale of investment

in third party - 12,291

Sales and maturities of

available-for-sale investments 7,596 28,212

Purchases of available-for-sale

investments - (71,398)

Net cash used for investing

activities (79,910) (200,934)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 37,185 74,375

Windfall tax benefits from

stock-based compensation 4,592 9,934

Acquisition of treasury stock (24) (128)

Payments on and retirements of

long-term debt (216,093) (2,902)

Net cash (used for) provided

by financing activities (174,340) 81,279

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS (601) 10,804

NET INCREASE IN CASH AND CASH

EQUIVALENTS 27,926 165,470

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 818,669 496,512

CASH AND CASH EQUIVALENTS, END OF

PERIOD
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... serious infectious diseases, announced today that Jeffrey Riley , ... New York Conference on Thursday, June 27, 2013 at The ... Mr. Riley is scheduled to present at 8:40 a.m. (Eastern ... can be accessed by logging onto the web at ...
(Date:6/19/2013)... , June 19, 2013 MO BIO ... and other challenging microbial nucleic acid purification, announces ... Kit, for extraction of pure protein from all ... coincides with the 20 th anniversary of ... capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ) ...
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
(Date:6/19/2013)... --  NineSigma , Inc., of Cleveland ... NineSights.com is now the innovation engine for ... community of innovators. From technology developers, to ... stands out for its large community of innovators in ... all vetted by NineSigma. The community is free to ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3
... SOUTH PLAINFIELD, N.J., Aug. 10 PTC Therapeutics, Inc. ... its collaboration with Schering-Plough Corporation (NYSE: SGP ) receiving a ... for the treatment of hepatitis C virus (HCV) infection. , ... rnh/20010919/PTCLOGO ) , , The collaboration ...
... SHANGHAI, Aug. 10 /PRNewswire-Asia-FirstCall/ -- ... "the Company"), a leading Chinese firm,specializing in ... probiotics products, today announced that the Company,s,wholly-owned ... been,awarded the High-Technology Enterprise Certificate (the "Certificate") ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration 2PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration 3China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3
(Date:6/19/2013)...  New York College of Health Professions announces the ... Trademark Office for detecting biometric changes through smart phones, ... been injured, attacked or killed. This patent ... Properties Agreements of New York College of Health Professions. ... New York College says, "Our Chairman, ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
(Date:6/19/2013)... Midwest are expected to contribute to a very large ... according to a University of Michigan ecologist and colleagues ... for the Chesapeake Bay. , The Gulf forecast, one ... Administration, calls for an oxygen-depleted, or hypoxic, region of ... it among the 10 largest on record. , The ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... by the International Osteoporosis Foundation (IOF) show alarming projections ... the Russian Federation and many other countries in the ... conference in St. Petersburg at the IOF Summit of ... Osteoporosis, a disease of the bone which leaves people ...
... Santa Cruz, CA, USA and Oxford, UK, 27 September ... shows a new method of enzyme-controlled movement of ... The paper, by researchers at the University of ... nanopore sequencing of DNA strands. The publication describes the ...
... Carolina State University researcher has shown that water-gel-based solar ... cells to produce electricity. The findings prove the concept ... They also have the potential to be less expensive ... solar cells. The bendable devices are composed of ...
Cached Biology News:High death and disability rates due to fractures in Russia, Central Asia and Eastern Europe 2Nature Nanotechnology paper shows enzyme-controlled movement of DNA polymer through a nanopore 2Mimicking nature, water-based 'artificial leaf' produces electricity 2
... Ideal for hand-held applications or for use ... with a hand-held eight-port disposable manifold provides ... a multi-channel pipette. The StatMatic II can ... sizes and can completely fill a microplate ...
...
... tube gel adaptors, 24 glass tubes ... grommets, stoppers. The PROTEAN II xi cell ... the versatility to perform a variety of ... electrophoresis, native, preparative, and gradient PAGE as ...
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
Biology Products: